Incannex Healthcare Inc. (IXHL) Tuesday reported positive data from its Phase 2 study of PSX-001 a psilocybin-assisted psychotherapy treatment for generalised anxiety disorder.
In the study, participants with generalised anxiety disorder were randomized to receive either PSX-00 or placebo. Results from the study showed that patients treated with PSX-001 achieved an average 12.8-point reduction in HAM-A (Hamilton Anxiety Rating Scale) scores from baseline, compared to a 3.6-point reduction in the placebo group. In 44.1% of patients, a 50% reduction in HAM-A score was observed, 4 times higher than the placebo group. Twenty seven percent of patients receiving PSX-001 achieved full disease remission, five times higher than placebo.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.